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Abstract 
From their early successes in medicine, organometallic compounds continue to attract interest as 
potential chemotherapeutics to treat a range of diseases. Here, we show from recent literature 
selected largely from the last 2 years that organometallics offer unique opportunities in medicine 
and, increasingly, a mechanistic-based approach is applied to their development, which has not 
always been the case.   
Introduction 
Organometallic compounds, i.e. compounds with a direct metal-carbon bond, have a long history in 
medicinal chemistry. Indeed, the first reported drug discovered from screening a library of 
compounds identified an organometallic as a potent antimicrobial. We refer here to the historically 
important discovery of the organoarsenic compound, Salvasan, by Paul Ehrlich via a mechanism-free 
approach [1].  Other organometallics, and metal-based drugs more generally, were subsequently 
identified with no or only limited mechanistic insights and, today, most have been superseded due 
to side-effects associated with their use [2]. Based on considerably more stringent therapeutic 
indexes required, combined with the incompatibility of many organometallics with high-throughput 
screening methods, mechanism-based organometallic drug design should now be considered as 
essential [3].  Importantly, organometallics offer certain structural characteristics [4, 5] or 
mechanistic pathways [6] that are inaccessible to other classes of compounds, and it is these unique 
pathways where there is most promise for new organometallic drugs with alternative or superior 
properties to other classes of compounds. Here, we have selected organometallics from the last two 
years which fulfil these criteria. Notably, these recently discovered compounds have not reached a 
level of maturity to enter the clinic, but we believe the approaches hold considerable promise and 
will lead to new therapeutics.  
Ruthenium organometallics – continuing to yield promising lead compounds 
Organometallic complexes based on ruthenium have emerged as some of the most promising 
alternatives to platinum-based anticancer agents, with half-sandwich structures being a major focus 
of this class.  The RAED and RAPTA series of compounds (Fig. 1(a)) sparked the development of a 
wide range of ruthenium-arene anticancer agents, with the half-sandwich structure permitting wide-
ranging structural variation through modulation of arene substituents and/or the remaining ligands 
occupying the ruthenium coordination sphere [7, 8]. 
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Figure 1 Chemical structures of half-sandwich metallodrugs; (a) the mononuclear RAED and RAPTA structures, (b) dinuclear 
RAPTA analogues which bind to the histone H2A–H2B dimer, (c) a plectin-targeting complex, (d) complexes exhibiting pH-
dependent reactivity towards 5’-GMP, (e) catalytic metallodrugs.  
From the outset the RAPTA compounds displayed a vastly different cytotoxicity profile to typical 
platinum chemotherapeutic agents; in general limited cytotoxicity observed within reasonable (0-
200 μM) dosing ranges in 2D cell culture experiments, but strong antimetastatic and antiangiogenic 
activity was observed in in vivo models, alongside activity against primary tumours when appropriate 
dosing regimens were employed [9]. While the RAED compounds appear to be abandoned, 
preclinical development of RAPTA compounds continues due to their unique pharmacological 
profiles, with RAPTA-T recently shown to modulate the tumor microenvironment allowing effective 
treatment of chemoresistant mesothelioma when combined with a cytotoxic platinum agent (which 
is essentially inactive in the absence of RAPTA-T) [10].  Although the full mechanism of action of 
RAPTA-T is complicated, like other RAPTA compounds, binding to the ‘acidic patch’ on the histone 
H2A–H2B dimer in the nucleosome, impacting on chromatin dynamics, has been observed, and even 
leads to major structural rearrangements that illicit allosteric binding [11].  More recently, a 
compound that bridges these allosteric sites was reported [12]. The binding constants of RAPTA-T 
are low and to strengthen binding dimeric compounds (Fig. 1(b)) were produced that bind 
considerably more strongly to the histone H2A–H2B dimer (Fig. 2) [13].  
 
 
Figure 2: Binuclear RAPTA compounds were found to form interprotein crosslinks in chromatin – crosslinking the H2A-H2B 
dimer.  Images correspond to close-up views of the histone interactions of the complexes (see figure 1(b)) constructed from a 
(1R,2R)-(+)-1,2-diphenylethylenediamine linker (left) and an ethylenediamine linker (right).  Figure adapted from ref. [13] under 
a Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/). 
New families of ruthenium-arene complexes are emerging that also exert unique activity through 
selectivity in their protein binding profile.  Meier et. al. have identified a family of ruthenium 
compounds with plectin, a cytolinker protein, as the major cellular target (Fig. 1(c)) [14].  Plectin 
targeting leads to G0/G1 arrest in HCT116 cells, with large changes to the cytoarchitecture.  In a 3D 
HCT116 tumour spheroid model, treatment resulted in reduced invasiveness, and also to reduced 
tumour volumes in murine colon carcinoma (CT-26) and B16 melanoma tumor models.  These 
results indicate the significant potential of this new family of ruthenium-arene compounds in the 
development of anticancer chemotherapeutics operating via novel mechanisms of action through 
interaction with a well-defined target.  
A series of recent reports have also outlined the development of ruthenium-arene compounds that 
display reactivity that is dependent on the local chemical environment (Fig. 1(d)). Towards exploiting 
the known extracellular pH differences between healthy (7.2-7.4) and cancerous (6.5-6.9) tissue, pH-
dependent coordination profiles have been demonstrated in complexes containing arene-tethered 
functionality able to reversibly form an intramolecular chelate in a pH-dependent manner. One set 
of complexes exploit the reversible formation of an η6:κ1-arene/N chelate to control the 
coordination of guanosine 5′-monophosphate (5′-GMP, used as a model for DNA) to the central 
ruthenium ion – with the open form able to readily coordinate to the nucleobase whereas the closed 
form remained unreactive [15].  However, under physiologically relevant conditions the closed form 
of these complexes predominates (ligand NH3+ pKa values of ~2.5) meaning they were unreactive 
towards 5′-GMP and inactive toward the A2780 ovarian cancer cell line.   
Control of 5′-GMP coordination to ruthenium across the physiologically relevant pH range has been 
achieved using complexes bearing a pendant sulfonamide functionality (Fig. 1(d)) [16]. Through 
variation of the sulfonamide substituent, the basicity of the sulphonamide nitrogen could be 
modulated, enabling tuning of the pH-region over which the intramolecular chelate form of the 
complex dominates and allowing pH-dependent regulation of 5′-GMP coordination to the central 
metal ion.  Further work is required to achieve complete control over ligand coordination as a 
function of pH as L-histidine coordination to the ruthenium was not controlled in a pH-dependent 
manner.  However, this work opens the way for the development of new organometallics able to 
selectively coordinate to a single class of biomolecular target. Other approaches to enhance the 
selectivity of ruthenium-arene chemotherapeutics based on light activated ruthenium-arene 
complexes have also been reported recently [17, 18]. 
Catalytic organometallics – promising low-dose chemotherapeutic agents 
Catalytic metal-based drugs that mimic metalloenzymes have made considerable advances towards 
clinical approval for a number of different conditions [19].  The use of metal complexes to catalyse 
biorthogonal transformations in living cells also represents a potentially powerful strategy toward 
the development of drugs with unique modes of action.  Recent examples of organometallic 
complexes catalysing biorthogonal transformations include ruthenium-cyclopentadienyl complexes 
for the catalytic deprotection of alloc- and allyl-protected amines in HeLa or 4T1 (mouse mammary 
carcinoma) cells [20-22], and olefin metathesis in E. Coli., utilising an artificial metalloenzyme based 
around a biotinylated Hoveyda–Grubbs second-generation catalyst [23]. 
In the development of catalytic metallodrugs with anticancer activity, complexes able to catalyse 
transfer hydrogenation have emerged as promising prototypes.  Noyori-type ruthenium-arene 
complexes (Fig. 1(e)) were used to catalyse the reduction of NAD+ to NADH in A2780 cells using 
formate as the hydride donor. The mechanism of cell death was linked to reductive stress induced 
by modulation of the NAD+/NADH redox couple [24].  While the Noyori-type ruthenium-arene 
catalysts provide outstanding enantioselectivites, for this reaction non-chiral catalysts are sufficient, 
and since these catalysts suffer from low catalytic rates, it is likely that more efficient transfer 
hydrogenation catalysts (with respect to turnover frequencies) would be even more effective. 
Related organometallic osmium(II)-arene complexes (Fig. 1(e)) were subsequently shown to 
enantioselectively reduce pyruvate to lactate in A2780 cells, utilising sodium formate as a hydride 
source [25].  Interestingly, the resulting antiproliferative effect observed on complex and formate 
administration to A2780 cells was found to be significantly reduced in MRC-5 lung fibroblasts and 
human ovarian fibroblasts (HOF), indicative of selectivity toward the cancer cell line.  Although the 
specific cause of cell death was not identified, and could be due to interactions of the catalyst with 
DNA or proteins, this study highlights the potential of catalytic metallodrugs as a strategy by which 
high efficacy may be achieved, and where drug resistance may possibly be overcome through 
multiple unprecedented mechanisms of action. While small molecule organometallic catalytic drugs 
have been most extensively studied, artificial metalloenzyme drugs hold considerable promise and 
could potentially offer even greater benefits in the long-term [26]. 
In an alternative approach, an organoiridium(III) photocatalyst, [Ir(ttpy)(pq)Cl]+, photocatalytically 
oxidizes 1,4-dihydronicotinamide adenine dinucleotide (NADH) to generate NAD• radicals, a process 
that has been shown to take place in the mitochondria of cells upon irradiation with blue light, as 
the compound accumulates in the mitochondria [27]. Metal containing photocatalysts 
(photosensitizers) employed in the clinic [28], or under clinical evaluation [29], are usually activated 
by red light as this penetrates tissue most effectively. The classical mechanism of action of 
photosensitizers involves the photocatalytic generation of HO2• or O2•- from O2 (Type I mechanism) 
and generation of 1O2 from 3O2 (Type II mechanism) in endothelial cells, which close the blood 
vessels around the tumor via oxidative damage to cut off the supply of nutrients [30], whereas 
[Ir(ttpy)(pq)Cl]+ functions in hypoxic environments directly inside cancer cells and potentially opens 
the way to new phototherapy strategies.  
Rhenium tricarbonyl compounds – an emerging class of metallodrug 
The anticancer activity of organometallic rhenium compounds is much less explored than that of 
group 8 and 10 metal compounds, but recent reports illustrate the progress achieved with this 
element.  Notably, a series of rhenium(I) tricarbonyl complexes were discovered that induce cell 
death in a manner distinct to that exerted by cisplatin, and which circumvent cisplatin resistance in 
KBCP20, A2780CP70, A549CisR and H460 cell lines [31, 32].  Studies on one of the complexes (Fig. 3) 
revealed its ability to coordinate to 9-ethylguanine, N-acetylcysteine and N-acetylhistidine, that it 
localises within the mitochondria and induces cell death in a manner that is caspase-independent.  
The biodistibution of this complex was examined in naïve C57B16 mice using both 99mTc and Re 
analogues – non-specific uptake was not detected in the examined organs  and rapid hepatic and 
renal clearance was observed (over 120 minutes post-injection).  Antitumour activity was evaluated 
in NOD scid gamma mice using ovarian cancer patient-derived zenografts.  Dosing at 10 mg/kg twice 
per week led to reduced tumour volume without loss in body weight over 30 days, although tumour 
weights were unexpectedly no different to that of untreated controls and this was attributed to an 
increase in the density of treated tumours.  No side effects were observed during the treatment 
regime although the rhenium content in the tumours was lower than in most organs (kidneys, heart, 
lung, liver).  It is clear that while this compound can significantly influence tumour size, its inability to 
decrease tumour weight coupled with off-target accumulation of rhenium could limit future 







Figure 3.  A recently reported rhenium(I) tricarbonyl complex (left) that causes a significant reduction in tumour volume (right) 
but not weight when administered in the range 10-40 mg/kg. Right-hand image adapted with permission from Konkankit CC, 
King AP, Knopf KM, Southard TL, Wilson JJ: In Vivo Anticancer Activity of a Rhenium(I) Tricarbonyl Complex. ACS Med 
Chem Lett 2019, 10: 822−827. Copyright 2019 American Chemical Society. 
Silver and gold complexes targeting multiple cancer-related pathways 
N-heterocyclic carbene (NHC) complexes based on silver and gold have emerged as an area of focus 
for the development of new anticancer chemotherapeutics [33, 34].  A recent report [35] outlined 
the activity of a silver-NHC complex [36] (Fig. 4(a)) able to exert anticancer activity via interactions 
with multiple targets.  The complex was found to efficiently inhibit purified thioredoxin reductase 1 
(TrxR1), human topoisomerase I and II and human PARP-1, all significant prospective intracellular 
targets.  Cellular ROS levels increased on treatment with the complex and selective inhibition of 
glycolysis in cancer cells (A2780 and OVCAR3) was observed compared to non-cancer cell lines.  The 
complex was well tolerated in mice and anticancer activity was observed against ovarian cancers 
using the hollow fibre assay where fibres were implanted intraperitoneally (note that anticancer 
activity was not observed with fibres implanted subcutaneously).  Given the metallodrug was 
tolerated well in vivo, whilst exerting activity via multiple DNA-damaging mechanisms, this silver-
NHC complex is a lead structure worth further investigation and may yield a new family of 
metallodrugs able to overcome resistance issues afflicting platinum-based drugs. However, it should 
be noted that many metal-based drugs are able to inhibit the proteins listed above to varying 
degrees, and they do not necessarily correspond to the actual targets. Indeed, certain metals have 
been described as promiscuous [37], able to bind to many isolated proteins, and the major 
intracellular targets should ideally be identified from proteomics studies [38].  The demonstration 
that rational targeting of multiple cancer-related pathways can lead to highly effective metallodrugs 
is an important principle and suggests those exhibiting promiscuous activity may hold a certain 
advantage over those designed to act on a single target, as long as cancer cell selectively can be 
maintained. In this respect, in the treatment of cancer targeted drugs, i.e. drugs that selectively bind 
to a single enzyme/protein, tend to be applied in combination with broad acting drugs such as the 
clinically approved platinum-based drugs [39].  Recent studies have also highlighted the considerable 
potential of platinum-based drugs combined with immunotherapy [40]. 
 
Figure 3.  Recent examples of (a) silver and (b) gold organometallics assessed in vivo. 
A dual targeting approach has been recently employed to rationally devise Au-NHC TrxR inhibitors 
that lead to the promotion of singlet oxygen generation [41].  The combination of a quinone-NHC 
moiety, as a redox cycling agent, and Au(I) centre (Fig. 4(b)), to coordinate within the TrxR active 
site, led to metallodrugs more active than doxorubicin against the A549 lung cancer cell line, and 
highly active against other cancer cell lines.  In a zebrafish tumor xenograft model the Au-NHC 
complex was well tolerated and induced apoptosis in tumor xenografts.   
Conclusions and future prospects 
From a survey of recent literature, research encompassing the anticancer activity of organometallic 
compounds is flourishing and making significant progress [42-45].   Creative and novel strategies to 
enhance the efficacy and selectivity of small molecule organometallics show promise in animal 
models, with examples being well tolerated and doses well below maximum tolerated doses 
resulting in good antitumor activity.  There is a clear trend for developing organometallics able to 
operate via multiple simultaneous mechanisms of action to exert anticancer activity, despite exciting 
prospects of organometallics designed to interact with a single target [46].  Multifactorial strategies 
offer benefits in overcoming cellular resistance and in, potentially, accessing low-dose therapeutic 
regimens, that are likely to be used in combination with targeted drugs, and the future of the field 
surely lies in this domain.  There are still major challenges to be met to prevent off-target 
metallodrug accumulation and/or in the selective activation of a metallodrug in solely the target 
tumor environment.  However, recent developments in the design of cancer cell specific prodrug 
activation and catalytic metallodrugs offer significant promise and are likely to inspire a new 
generation of prospective organometallotherapeutics. The most advanced organometallic 
compound, with respect to clinical development, is an antimalarial termed ferroquine, in which a 
ferrocenyl moiety replaces a phenyl ring in chloroquine to restore activity in resistant parasites. 
Although not covered in this review, ferrocene compounds have been extensively studied in 
medicinal chemistry [47]. Finally, whilst none of the compounds described in this review have yet 
reached the stage of clinical trials, organometallics have been evaluated on humans in relation to 
other diseases, and therefore the rapid progress of the field in recent years suggests these studies 
are not far away.  
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